摘要
目的:探究热灌注化疗法对胃癌患者血管内皮生长因子受体1(vascular endothelial growth factor receptor 1,VEGFR-1)及基质金属蛋白酶(matrix metalloproteinases 9,MMP-9)等的影响.方法:选取2010-03/2013-04于郑州大学第五附属医院就诊的胃癌患者86例,依据分层随机分组法将患者分为治疗组及对照组,每组43例.给予对照组常规化疗方案进行治疗;给予治疗组热灌注化疗方案进行治疗.观察比较两组患者治疗前后的糖链抗原72-4(CA72-4)值、VEGFR-1及MMP-9阳性例数变化以及患者临床症状及不良反应情况.结果:治疗前两组患者的C A72-4值、VEGFR-1及MMP-9阳性例数以及腹水例数比较差异无统计学意义(P>0.05);治疗后治疗组患者的CA72-4值、VEGFR-1及MMP-9阳性例数、腹水例数分别是5.43 kU/L±2.07 kU/L、18.60%、23.26%、7例,对照组依次是7.08 kU/L±3.19 kU/L、41.86%、44.19%、15例,治疗组均低于对照组(P<0.05);治疗后治疗组6 mo复发率及1年复发率为2.33%、13.95%,对照组分别是18.6%、32.56%,治疗组低于对照组;治疗组患者6 mo生存率及1年生存率分别是88.37%、67.44%,对照组分别是69.77%、44.19%,治疗组均高于对照组(P<0.05);治疗组治疗过程中出现消化道出血2例及腹痛例数5例均小于对照组9例、13例,差异有统计学意义(P<0.05);治疗组出现白细胞减少1例及腹泻2例,不良反应例数均低于对照组9例、9例,差异有统计学意义(P<0.05).结论:应用热灌注化疗法相对于常规化疗法可达到更好的治疗效果,降低患者VEGFR-1及MMP-9水平,明显减轻患者临床症状,降低复发率.
AIM： To explore the effect of hyperthermic per-fusion chemotherapy on vascular endothelialgrowth factor receptor 1（VEGFR-1） and matrixmetalloproteinase 9（MMP-9） in patients withgastric cancer. METHODS： Eighty-six gastric cancer patientstreated at our hospital from March 2010 to April2013 were randomly divided into either a treat-ment group or a control group, with 43 casesin each group. The control group was givenconventional chemotherapy, and the treatment group was given hyperthermic perfusion che-motherapy. Carbohydrate antigen 72-4（CA72-4）, VEGFR-1 and MMP-9, changes in clinical symp-toms and adverse reactions were compared be-tween before and after treatment. RESULTS： There were no significant differ-ences in CA72-4 value, the percentages of VEG-FR-1 or MMP-9 positive cases, or the number of cases with ascites between the two groups before treatment（P〈0.05）. CA72-4 value, the percentages of VEGFR-1 and MMP-9 positive cases, and the number of cases with ascites were significantly lower in the treatment group than in the control group（5.43 kU/L ± 2.07 kU/L vs 7.08 kU/L ± 3.19 kU/L, 18.60% vs 41.86%, 23.26% vs 41.86%, 7 vs 15, P〈0.05）. The recur-rence rates at 6 mo and 1 yr were significantly lower in the treatment group than in the con-trol group（2.33% vs 18.6%, 13.95% vs 32.56%, P〈0.05）, while the survival rates at 6 mo and 1 yr were significantly higher in the treatment group（88.37% vs 69.77%, 44.19% vs 67.44%, P〈0.05）. The numbers of cases with gastrointesti-nal bleeding, abdominal pain, leukopenia and diarrhea were significantly less in the treatment group than in the control group（2 vs 9, 5 vs 13, 1 vs 9, 2 vs 9, P〈0.05）. CONCLUSION： Hyperthermic perfusion che-motherapy can achieve better effects than con-ventional chemotherapy in patients with gastric cancer, and it can reduce the levels of VEGFR-1and MMP-9, relieve clinical symptoms and de-crease the relapse rate.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第24期3654-3659,共6页
World Chinese Journal of Digestology
基金
郑州市2010年度科研发展规划基金资助项目
No.2010SFXM345~~
关键词
热灌注化疗
胃癌
血管内皮生长因子受体
复发
Perfusion chemotherapy
Gastric can-cer
Vascular endothelial growth factor receptor
Relapse
